Oral Anti-Diabetic Drugs Market

Market Overview The Global Oral Anti-Diabetic Drugs Market is projected to expand significantly from USD 18.67 Billion in 2025 to USD 28.07 Billion by 2031, demonstrating a robust 7.03% CAGR. These orally administered pharmaceutical agents are crucial for managing blood glucose levels in Type 2 diabetes patients by boosting insulin secretion, enhancing insulin sensitivity, or curbing glucose absorption. This market growth is primarily fueled by the increasing global prevalence of Type 2 diabetes, which affected approximately 589 million adults aged 20 to 79 worldwide in 2025 according to the International Diabetes Federation, representing 11.1% of the adult population. This widespread incidence, linked to aging populations and sedentary lifestyles, creates continuous demand for effective oral therapies and contributes to a global expenditure on diabetes-related healthcare estimated at USD 1 trillion in 2025. Further propelling the market are advancements in novel oral drug classes and formulations, such as the successful oral formulation of GLP-1 receptor agonists, which replace invasive injectable treatments, thereby improving patient adherence and expanding market reach. Evidence of this shift is seen in Novo Nordisk's Q3 2025 financial report, which recorded Rybelsus sales of DKK 5,442 million. Market Driver The escalating global prevalence of Type 2 diabetes serves as the primary driver propelling the Global Oral Anti-Diabetic Drugs Market. This expanding disease burden is inextricably linked to rising obesity rates and sedentary lifestyles, creating a continuous demand for effective oral glucose-lowering therapies. As the patient demographic requiring lifelong management widens, the reliance on accessible pharmaceutical interventions intensifies to mitigate long-term health complications. According to the International Diabetes Federation, December 2025, in the 'IDF Diabetes Atlas 11th Edition', it was revealed that 11.1% of the adult population worldwide is currently living with diabetes. This widespread incidence translates into substantial economic activity within the healthcare sector. According to the International Diabetes Federation, in 2025, global expenditure on diabetes-related healthcare was estimated to be approximately USD 1 trillion, underscoring the massive financial resources directed toward therapeutic management and disease control.Advancements in novel oral drug classes and formulations represent the second critical driver, fundamentally reshaping patient care by replacing invasive delivery methods with convenient oral options. Innovation in this sector is enabling the successful formulation of complex molecules, such as GLP-1 receptor agonists, into tablets, thereby overcoming the historical barriers associated with injectable treatments. This technological shift significantly improves patient adherence and expands the addressable market for advanced therapies beyond traditional injectables. The rapid commercial adoption of these formulations is reflected in recent corporate performance data. According to Novo Nordisk, November 2025, in the 'Q3 2025 Financial Report', sales of Rybelsus, a prominent oral GLP-1 therapy, reached DKK 5,442 million in the third quarter alone, demonstrating the strong market preference for effective, non-invasive treatment modalities. Market Challenge The limited affordability of advanced oral anti-diabetic medications in low- and middle-income countries presents a substantial barrier to revenue growth for pharmaceutical manufacturers. Although these regions represent a rapidly expanding patient base, restricted healthcare budgets and insufficient reimbursement frameworks often prevent the wide adoption of premium drug classes. Consequently, healthcare providers and patients frequently prioritize cost-effective generic alternatives over newer branded therapies to manage treatment costs. This economic pressure significantly limits the market penetration of high-value products and constrains the commercial return on investment for developers of novel treatments.This disparity creates a clear disconnect between regional disease burden and actual market value, hindering the ability of companies to monetize innovation in high-volume territories. According to the International Diabetes Federation, in 2025, low- and middle-income countries accounted for only 9.3% of global diabetes-related health expenditure despite hosting the majority of the global diabetic population. This lack of purchasing power forces the market to rely heavily on volume rather than value, thereby reducing profit margins for major industry players and dampening the overall financial expansion of the global sector. Market Trends The expanding utilization of SGLT2 inhibitors is reshaping the market as clinical guidelines increasingly prioritize these agents for cardio-renal benefits rather than solely for glycemic control. Physicians are prescribing these therapies to mitigate heart failure and chronic kidney disease, transitioning the drug class to a fundamental pillar of cardio-metabolic management. This shift significantly amplifies revenue for incumbents securing label expansions for these comorbidities, effectively creating a new growth vertical beyond traditional diabetes care. According to AstraZeneca, November 2024, in the 'Q3 2024 Results', expanding demand for heart failure and kidney disease treatments drove Farxiga revenue to grow by 27% in the third quarter, confirming the commercial impact of this broader therapeutic application.Concurrently, the acceleration of generic market entry following patent expiries for blockbuster dipeptidyl peptidase-4 (DPP-4) inhibitors is structurally altering the sector. The expiration of key protections has triggered an influx of cost-effective alternatives, rapidly eroding the share of established brands while broadening patient access. This pressure forces originators to pivot strategies as value shifts away from mature assets toward newer, protected drug classes. According to Merck & Co., October 2024, in the 'Third-Quarter 2024 Financial Results', sales of the branded therapy Januvia declined by 49% to USD 278 million, primarily reflecting the intense impact of generic competition in the United States and international markets. Key Market Players * KONINKLIJKE PHILIPS N.V. * Sanofi S.A. * Eli Lilly and Company * AstraZeneca Plc. * Astellas Pharma Inc. * Johnson & Johnson * C.H. Boehringer Sohn AG & Co. KG * Merck And Co. Inc. * Bristol Myers Squibb Company * Novartis AG Report Scope In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Oral Anti-Diabetic Drugs Market, By Drugs * Biguanides * Alpha-glucosidase inhibitors * Dopamine -D2 Receptor Agonist * Sodium-glucose Cotransport -2 (SGLT-2) inhibitor * Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors * Sulfonylureas * Meglitinides # Oral Anti-Diabetic Drugs Market, By End Users * Hospitals * Homecare * Speciality Centers * Others # Oral Anti-Diabetic Drugs Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market. Available Customizations: Global Oral Anti-Diabetic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).